Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial.

J Gastroenterol · 2011 · PMC3117278 · PMID 21499703

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantP < 0.001actually significant

The HR of the lansoprazole group relative to the gefarnate group was estimated as 0.099 (95% CI 0.042–0.230)—a 90.1% risk reduction, and the difference was highly significant (log-rank test, P < 0.001) (Table 2 ; Fig. 2 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.